marked.bio

Mutation in BRAF

BRAF V600E

196 active trials select patients by BRAF V600E or a broader group, and 104 of them are recruiting. 17 FDA and 13 EU approvals name it.

Trials as of 2026-10-27. Seen most often in melanoma, colorectal, NSCLC, thyroid, tumor-agnostic.

Active trials by phase
Early Phase 1: 5 active trialsEarly 15Phase 1: 35 active trials135Phase 1/2: 31 active trials1/231Phase 2: 96 active trials296Phase 2/3: 3 active trials2/33Phase 3: 15 active trials315Phase 4: 1 active trials41N/A: 10 active trialsNo phase10
Trials started per year (2026 so far)
2010: 16 trials started20102011: 21 trials started2012: 35 trials started2013: 51 trials started512014: 34 trials started2015: 21 trials started20152016: 28 trials started2017: 29 trials started2018: 32 trials started2019: 20 trials started2020: 45 trials started20202021: 46 trials started2022: 40 trials started2023: 34 trials started2024: 36 trials started2025: 23 trials started2026: 16 trials started162026

Approved therapies

Approvals in the United States (FDA) and the European Union (EMA), one row per drug, regimen and tumour type. Open a row for the exact indication and source.

TherapyTumourUnited StatesEuropean Union
vemurafenib
FDA, 2017
BRAF V600 mutation Label 1.2: ECD with BRAF V600 mutation. No EU equivalent. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source
ZelborafBroader label 		Erdheim-Chester disease Approved 2017To verify Not approved
dabrafenib with trametinib
FDA, 2017
metastatic, BRAF V600E Label 1.4. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source
EU (EMA), 2017
advanced, BRAF V600 mutation EU label says 'BRAF V600 mutation' (broader than the FDA's V600E). WS/0996, EC decision 29/03/2017. Source
Tafinlar 		NSCLC Approved 2017To verify Approved 2017
encorafenib with binimetinib
FDA, 2023
metastatic, BRAF V600E FDA approval 11/10/2023. Source
EU (EMA), 2024
advanced, BRAF V600E WS/2538 (Braftovi + Mektovi), EC decision 29/08/2024. Source
Braftovi 		NSCLC Approved 2023 Approved 2024
dabrafenib with trametinib
FDA, 2018
locally advanced or metastatic, BRAF V600E, no satisfactory locoregional options FDA approval 04/05/2018 (regular); current label 1.5. No EU equivalent. Source
Tafinlar 		anaplastic thyroid cancer Approved 2018 Not approved
encorafenib with cetuximab
FDA, 2020
metastatic, BRAF V600E, after prior therapy Label 1.2 second bullet: with cetuximab after prior therapy. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source
EU (EMA), 2020
metastatic, BRAF V600E, after prior systemic therapy WS/1695, EC decision 02/06/2020. Source
Braftovi 		colorectal Approved 2020To verify Approved 2020
encorafenib with cetuximab + FOLFOX
EU (EMA), 2026
first line, metastatic, BRAF V600E EMA/VR/0000304994: CHMP opinion 21/05/2026, EC decision 19/06/2026. EU wording: cetuximab and FOLFOX. Source
Braftovi 		colorectal Not approved Approved 2026
encorafenib with cetuximab + fluorouracil-based chemotherapy
FDA, 2024
metastatic, BRAF V600E (label no longer states line; based on first-line BREAKWATER) AA 20/12/2024 with cetuximab + mFOLFOX6; converted to traditional approval 24/02/2026 and regimen broadened to cetuximab + fluorouracil-based chemotherapy. Source
Braftovi 		colorectal Approved 2024 Not approved
dabrafenib with trametinib
EU (EMA), 2026
locally advanced or metastatic, BRAF V600E, refractory to or not eligible for radioactive iodine, progressed during/after prior systemic therapy Worksharing EMA/VR/0000278305 (Tafinlar + Mekinist): CHMP opinion 26/03/2026, EC decision 30/04/2026. No FDA DTC indication. Source
Tafinlar 		differentiated thyroid cancer Not approved Approved 2026
atezolizumab with cobimetinib + vemurafenib
FDA, 2020
unresectable or metastatic, BRAF V600 mutation-positive Label 1.4: BRAF V600 mutation-positive. No EU equivalent. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source
FDA, 2024
unresectable or metastatic, BRAF V600 mutation-positive Subcutaneous atezolizumab approved 12/09/2024 for all adult IV Tecentriq indications, including melanoma; label 1.4. Source
Tecentriq, Tecentriq HybrezaBroader label 		melanoma Approved 2020To verify Not approved
cobimetinib with vemurafenib
FDA, 2015
unresectable or metastatic, BRAF V600E or V600K Label 1.1. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source
EU (EMA), 2015
unresectable or metastatic, BRAF V600 mutation MA 20/11/2015. Source
CotellicBroader label 		melanoma Approved 2015To verify Approved 2015
dabrafenib
FDA, 2013
unresectable or metastatic, BRAF V600E (monotherapy) Label 1.1 single agent, BRAF V600E. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source
EU (EMA), 2013
unresectable or metastatic, BRAF V600 mutation MA 26/08/2013. EU label now covers adults and adolescents >=12 years. Source
Tafinlar 		melanoma Approved 2013To verify Approved 2013
dabrafenib with trametinib
FDA, 2014
unresectable or metastatic, BRAF V600E or V600K AA 09/01/2014, converted to regular approval 20/11/2015 (FDA Verified clinical benefit list); label 1.2 BRAF V600E or V600K. Source
FDA, 2018
adjuvant, BRAF V600E or V600K, lymph node involvement, after complete resection Label 1.3 wording: melanoma with lymph node involvement following complete resection (not 'stage III'). Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source
EU (EMA), 2015
unresectable or metastatic, BRAF V600 mutation WS/0736, EC decision 25/08/2015. Source
EU (EMA), 2018
adjuvant, stage III, BRAF V600 mutation WS/1274, EC decision 27/08/2018. Source
TafinlarBroader label 		melanoma Approved 2014To verify Approved 2015
encorafenib with binimetinib
FDA, 2018
unresectable or metastatic, BRAF V600E or V600K Label 1.1 with binimetinib, BRAF V600E or V600K. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source
EU (EMA), 2018
unresectable or metastatic, BRAF V600 mutation MA 19/09/2018. Source
BraftoviBroader label 		melanoma Approved 2018To verify Approved 2018
vemurafenib
FDA, 2011
unresectable or metastatic, BRAF V600E Label 1.1: BRAF V600E (not indicated for wild-type). Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source
EU (EMA), 2012
unresectable or metastatic, BRAF V600 mutation-positive MA 17/02/2012. EU label: BRAF V600 mutation-positive. Source
Zelboraf 		melanoma Approved 2011To verify Approved 2012
dabrafenib with trametinib
FDA, 2023
BRAF V600E, requiring systemic therapy, age >=1 FDA approval 16/03/2023 (regular; label 1.7). Source
EU (EMA), 2023
low-grade glioma needing systemic therapy, and high-grade glioma after >=1 prior treatment, BRAF V600E Finlee MA 15/11/2023 covering LGG (needing systemic therapy) and HGG (after >=1 prior radiation and/or chemotherapy), BRAF V600E, age >=1. Trametinib paediatric formulation is Spexotras in the EU. Source
Finlee, Tafinlar 		paediatric low-grade glioma Approved 2023 Approved 2023
tovorafenib
FDA, 2024
relapsed or refractory, BRAF fusion/rearrangement or BRAF V600 mutation, age >=6 months AA 23/04/2024; still on FDA Ongoing accelerated approvals list. Source
EU (EMA), 2026
progressed after >=1 prior systemic therapy, BRAF fusion/rearrangement or BRAF V600 mutation, age >=6 months Conditional MA 20/04/2026. Source
OjemdaBroader label 		paediatric low-grade glioma Approved 2024 accelerated Approved 2026 conditional
dabrafenib with trametinib
FDA, 2022
unresectable or metastatic BRAF V600E, progressed after prior treatment, age >=6 (later >=1) AA 22/06/2022, still on FDA Ongoing accelerated approvals list; label 1.6 now covers adults and children >=1 year (expanded 16/03/2023). No EU tumour-agnostic equivalent. Source
Tafinlar 		solid tumours (tumour-agnostic) Approved 2022 accelerated Not approved

Companies

Industry sponsors leading active trials, by number of trials. Each square is one trial, shaded by phase.

  1. Pfizer 5
  2. Haisco Pharmaceutical Group 4
  3. Novartis 2
  4. Pierre Fabre Medicament 2
  5. CSPC 2
  6. HiFiBiO Therapeutics 2
  7. CarThera 1
  8. OSE Immunotherapeutics 1
  9. Replimune 1
  10. Scancell 1
  11. Shanghai Fosun Pharmaceutical Industrial Development 1
  12. Shanghai Kechow Pharma 1
  13. Day One Biopharmaceuticals 1
  14. Fore Biotherapeutics 1
  15. Rapa Therapeutics 1

Trials

Matched automatically from registry text, so a few trials may only mention BRAF V600E rather than require it. Check the quoted criterion, and the registry entry before relying on a match.

196 of 589 trials shown

  1. Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

    Not yet recruiting Phase 4 Fujian Medical University Started 2025 NCT07010393

    Dabrafenib FDA EUTrametinibSelpercatinibPralsetinibLenvatinibLarotrectinib

    BRAF V600E mutation

    Thyroid Neoplasms

  2. FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

    Not yet recruiting Phase 3 Shanghai Fosun Pharmaceutical Industrial Development Started 2025 NCT07004075

    LuvometinibChemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide

    KIAA1549-BRAF fusion or BRAF V600E mutation-positive.

    Low-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration

  3. Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

    Recruiting Phase 3 University of Campania Luigi Vanvitelli Started 2025 NCT07389265

    Erbitux (Cetuximab)BevacizumabFOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

    RAS (NRAS and KRAS exon 2,3 and 4), BRAFV600E, PIK3CA, EGFR ECD wild-type and HER2 not amplified in liquid biopsy at the time of screen…

    Metastatic Colorectal Cancer (mCRC)

  4. Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma

    Not yet recruiting Phase 2/3 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Started 2025 NCT06819605

    Dabrafenib and trametinib (combination) FDA EU

    Presence of BRAF V600E mutation confirmed by next-generation sequencing (NGS) in tumor tissue.

    Ameloblastoma

  5. Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

    Recruiting Phase 3 ECOG-ACRIN Cancer Research Group Started 2024 NCT06475989

    CabozantinibDabrafenib FDA EUTrametinib

    Patient must have differentiated thyroid cancer (DTC) with BRAF V600E mutation as determined by local testing, including the following subtypes (Note: results …

    Refractory Differentiated Thyroid Gland Carcinoma

  6. Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy

    Recruiting Phase 3 The Netherlands Cancer Institute Started 2024 NCT06857773

    Intra arterial infusion Floxuridine (FUDR) combined with systemic therapySystemic therapy (standard of care)

    Known mutation status of RAS and BRAFV600E.

    Colorectal Neoplasms, Floxuridine, Liver Metastases, Vascular Access Device

  7. Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

    Active, not recruiting Phase 2/3 Alliance for Clinical Trials in Oncology Started 2023 NCT05710406

    Encorafenib FDA EUCetuximab

    BRAF V600E mutation

    Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8

  8. Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

    Recruiting Phase 3 Shanghai Kechow Pharma Started 2023 NCT06008119

    Tunlametinib plus Vemurafenib FDA EUDoublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab

    Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

    Colorectal Cancer Metastatic

  9. Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

    Active, not recruiting Phase 3 Pierre Fabre Medicament Started 2022 NCT05270044

    Encorafenib and Binimetinib FDA EU

    Available tumour sample for central determination of the BRAF V600E/K mutation.

    Status may be outdated, last updated 2023-11-22Melanoma

  10. Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

    Active, not recruiting Phase 3 Novartis Started 2021 NCT04940052

    Dabrafenib FDA EUTrametinibTrametinib PlaceboDabrafenib placebo FDA EU

    BRAF V600E mutation-positive tumor sample as per central laboratory result

    Differentiated Thyroid Cancer (DTC)

  11. A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

    Active, not recruiting Phase 3 Pfizer Started 2021 NCT04657991

    Encorafenib FDA EUBinimetinibPembrolizumab

    Documented evidence of a BRAF V600E or V600K mutation in melanoma tumor tissue as previously determined by either PCR or NGS-…

    Melanoma

  12. A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

    Active, not recruiting Phase 3 Pfizer Started 2020 NCT04607421

    Encorafenib FDA EUCetuximabOxaliplatinIrinotecanLeucovorin5-FU

    Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation

    Neoplasms

  13. Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma

    Not yet recruiting Phase 2 Northwestern University Starts 2027 NCT07863765

    Enfortumab Vedotin

    For BRAF V600E mutated: 2 lines as TKIs and ≥ 1 line of immunotherapy allowed

    Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma

  14. A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

    Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2026 NCT07506109

    Ipilimumab N01SintilimabCetuximabDabrafenib FDA EU

    Documented microsatellite stable (MSS) and BRAF V600E mutation by prior genomic testing.

    BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable)

  15. Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

    Not yet recruiting Phase 2 Washington University School of Medicine Started 2026 NCT07886905

    Dabrafenib FDA EUTrametinibPembrolizumab

    BRAF-V600E positive by IHC.

    Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma

  16. A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

    Not yet recruiting Phase 2 Yanqiao Zhang Started 2026 NCT07229846

    AipalolitovorelizumabXELOX + BevacizumabmFOLFOX + BevacizumabFOLFOXIRI + BevacizumabOxaliplatin + Irinotecan + Capecitabine + Bevacizumab

    …y confirmed unresectable metastatic colorectal adenocarcinoma of MSS/pMMR type with known BRAF V600E mutation;

    Colorectal Cancer

  17. Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients

    Recruiting Phase 2 Sun Yat-sen University Started 2026 NCT07809893

    Ivonescimab +mFOLFOXIRI +celecoxib

    Genetic testing indicates a BRAF V600E mutation;

    Colorectal Cancer

  18. Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

    Recruiting Phase 1/2 St. Justine's Hospital Started 2026 NCT06666348

    Mirdametinib

    …mor) or PLGG with evidence of MAPK pathway alteration with the exception of patients with BRAF V600E mutation (based on molecular analysis of the tumor).

    Pediatric Low-grade Glioma

  19. A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases

    Recruiting Phase 2 Zhejiang University Started 2026 NCT07789210

    Neoadjuvant therapy of encorafenib plus cetuximab N01 and mFOLFOX6 FDA EU

    PMMR/MSS, BRAF V600E mutation, and both NRAS and KRAS wild-type;

    Colorectal Cancer, BRAF V600E Mutation Positive, Encorafenib, Cetuximab N01

  20. A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

    Not yet recruiting Phase 1/2 National Cancer Center Hospital East Started 2026 NCT07591597

    S-531011FruquintinibPembrolizumab

    For patients with BRAF V600E mutation: prior treatment with a BRAF inhibitor (encorafenib)

    Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer

  21. Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

    Recruiting Phase 2 Shanghai Junshi Bioscience Started 2025 NCT06868836

    JS207PemetrexedCarboplatin or cisplatinJS212

    … exon S768I or T790M mutation, 21 exon L858R or L861Q mutation), ALK fusion, ROS1 fusion, BRAF V600E mutation, NTRK fusion, MET14 exon skipping mutation, RET fusion, KRAS G12C mutation, HER-…

    Non-squamous Non-small Cell Lung Cancer

  22. A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

    Recruiting Phase 1/2 Anbogen Therapeutics Started 2025 NCT07244705

    ABT-301TislelizumabBevacizumab (Avastin)

    NOTE: Participants with BRAF V600E, HER2 amplification/ mutation, KRAS G12C mutation, NTRK gene fusion, RET fusion, may or m…

    Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), Immunotherapy

  23. Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer

    Recruiting Phase 2 Fudan University Started 2025 NCT06763029

    Irinotecan liposomes combined with cetuximab + vermofenib

    For BRAF V600E mutated patients with MSI-H, first-line immunotherapy with PD-1 or PD-L1 is required;

    Colorectal Cancer Metastatic

  24. A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer

    Active, not recruiting Phase 2 Blokhin's Russian Cancer Research Center Started 2025 NCT06967155

    • Drug: Dabrafenib • Drug: Trametinib • Drug: Cetuximab • Drug: Рanitumumab • Drug: Oxaliplatin • Drug: Irinotecan • Drug: Leucovorin • Drug: 5-FU FDA EU

    …nib and Trametinib, Anti-EGFR in the Second Line of Treatment of Patients With Metastatic BRAF V600E- Mutated Colorectal Cancer.

    Neoplasms

  25. A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

    Recruiting Phase 2 Blokhin's Russian Cancer Research Center Started 2025 NCT06978400

    mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy FDA EU

    Histologically confirmed colorectal adenocarcinoma that contains MSS and BRAF V600E mutation

    Neoplasms

  26. Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

    Recruiting Phase 2 Sun Yat-sen University Started 2025 NCT07150247

    Iparomlimab and TuvonralimabBevacizumab5-FluorouracilIrinotecan (drug)

    BRAF V600E mutation confirmed by tissue pathology or ctDNA testing (PCR or NGS)

    BRAF V600 Colorectal Cancer

  27. A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

    Not yet recruiting Phase 2 Vall d'Hebron Institute of Oncology Started 2025 NCT07178717

    Rechalange with bevacizumab + encorafenib FDA EU

    Presence of confirmed BRAF V600E mutation.

    Colo-rectal Cancer

  28. Ulixertinib in People With Histiocytic Neoplasms

    Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2024 NCT06411821

    Ulixertinib

    Concordance between cfDNA and tumor sequencing for BRAFV600E and non-BRAF mutations in histiocytic neoplasms has been documented by our group and othe…

    Histiocytic Neoplasms

  29. Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

    Recruiting Phase 2 City of Hope Medical Center Started 2024 NCT06440850

    Cobimetinib FDA EURecombinant Thyrotropin AlfaVemurafenib FDA EU

    Known positive BRAFV600E mutation (determined on a previous analysis and/or on a representative formalin-fixed par…

    Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma

  30. Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

    Recruiting Phase 2 West China Hospital Started 2024 NCT06341296

    Irinotecan Liposome5-FULVBevacizumab

    RAS/BRAF v600e mutant or right half colon cancer is known.

    Status may be outdated, last updated 2024-08-12Metastatic Colorectal Cancer

  31. Combination Therapy for BRAF-V600E Metastatic CRCm

    Recruiting Phase 2 Vall d'Hebron Institute of Oncology Started 2024 NCT06411600

    Encorafenib FDA EUCetuximabBevacizumab

    Presence of BRAF V600E mutation in tumor tissue previously determined according to the guidelines of each center…

    Metastatic Colorectal Cancer

  32. Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer

    Recruiting Phase 2 Shanghai Changzheng Hospital Started 2024 NCT06603376

    FOLFIRI + Vemurafenib + Cetuximab FDA EUFOLFIRI ± Bevacizumab

    Patients with BRAFV600E mutation confirmed by tissue or blood testing.

    Status may be outdated, last updated 2024-09-19Colorectal Carcinoma

  33. Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer

    Recruiting Phase 2 Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) Started 2024 NCT06207656

    EBC

    Presence of a BRAF V600E mutation confirmed as per standard of care according to international guidelines at any t…

    Status may be outdated, last updated 2024-10-21Colorectal Cancer

  34. Pembrolizumab in High-risk Thyroid Cancer

    Recruiting Phase 2 Istituti Clinici Scientifici Maugeri SpA Started 2024 NCT05852223

    Pembrolizumab

    multifocal papillary microcarcinoma with extra tumor extension (ETE) and known BRAF V600E mutation

    Differentiated Thyroid Cancer

  35. A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

    Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2024 NCT06561360

    Vemurafenib FDA EUObinutuzumabCladribineRituximab

    Presence of BRAF V600E mutation as confirmed by PCR, NGS or immunohistochemistry.

    Hairy Cell Leukemia

  36. Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

    Active, not recruiting Phase 2 Gruppo Oncologico del Nord-Ovest Started 2024 NCT06578559

    CetuximabEncorafenib FDA EU

    Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

    Colorectal Cancer

  37. Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

    Recruiting Phase 1/2 University of Utah Started 2024 NCT06194929

    DefactinibAvutometinibEncorafenib FDA EU

    Cohort B: BRAF V600E or BRAF V600K

    Cutaneous Melanoma, Brain Metastases

  38. Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

    Not yet recruiting Phase 1/2 Henan Cancer Hospital Started 2024 NCT06454890

    Anti-Trop2 CAR-NK cell

    For patients with negative driver genes (EGFR/ALK/ROS-1/BRAF V600E/MET exon 14 mutation/NTRK), failed first-line PD-1/PD-L1 immunotherapy combined with plat…

    Status may be outdated, last updated 2024-06-12Non-Small Cell Lung Cancer NSCLC

  39. Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy

    Not yet recruiting Phase 2 The Christie NHS Foundation Trust Started 2024 NCT06470880

    Adaptive Therapy

    BRAF p.V600E/K/R/D mutation confirmed (exact point mutation must be known)

    Status may be outdated, last updated 2024-06-24Melanoma

  40. Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

    Recruiting Phase 2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS Started 2024 NCT06640166

    encorafenib + cetuximab + FOLFIRI FDA EU

    presence of BRAF V600E mutation in tumor tissue (primary CRC and/or related metastasis) as previously determined…

    Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumor, Colorectal Adenocarcinoma

  41. EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

    Recruiting Phase 1/2 University Hospital, Lille Started 2024 NCT06448572

    EXL01

    …S1 (fusions), MET (METex14 mutations), HER2 (exon 20 insertions), RET (fusions), or BRAF (V600E mutations).

    Non-Small Cell Lung Cancer

  42. Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

    Recruiting Phase 2 Eva Marie Erfurth, MD, PhD Started 2023 NCT05525273

    Oral dabrafenib and trametinib FDA EU

    BRAF mutated V600E (valine 600 glutamine), verified immunohistochemically and by molecular genetic analysis

    Status may be outdated, last updated 2024-02-14Craniopharyngioma

  43. Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

    Recruiting Phase 2 Federation Francophone de Cancerologie Digestive Started 2023 NCT05706779

    Encorafenib Oral Capsule + Cetuximab FDA EU

    …m (supra-peritoneal) considered operable and histologically confirmed, localised, mutated BRAF V600E determined in a biopsy specimen and resectable after CT-scan assessment.

    Colorectal Cancer, BRAF V600E Mutation Positive

  44. NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

    Recruiting Phase 2 Leiden University Medical Center Started 2023 NCT06079333

    dabrafenib/trametinib FDA EU

    Confirmed presence of BRAFV600E/K mutation in primary tumor tissue.

    Status may be outdated, last updated 2023-10-12Anaplastic Thyroid Cancer

  45. Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

    Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Started 2023 NCT06653517

    Dabrafenib FDA EUTrametinib

    Diagnosed with solid/multicystic type ameloblastoma with confirmed BRAF V600E mutation by next-generation sequencing (NGS);

    Status may be outdated, last updated 2024-10-22Ameloblastoma, BRAF V600E Mutation Positive

  46. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    Recruiting Phase 2 Fore Biotherapeutics Started 2023 NCT05503797

    Plixorafenib

    Documented BRAF V600E mutation in tumor and/or liquid biopsy detected by an analytically validated test at CLIA…

    Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

  47. KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

    Recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2023 NCT05985109

    KN046regorafenib

    Cohort B: pMMR/MSS mCRC with BRAF V600E mutation, who failed fluoropyrimidine, oxaliplatin, and irinotecan treatments.

    Status may be outdated, last updated 2023-10-26Colorectal Cancer

  48. XTX301 in Patients With Advanced Solid Tumors

    Recruiting Phase 1/2 Xilio Development Started 2023 NCT05684965

    XTX301

    ROS1 fusion, NTRK fusion, BRAF V600E mutation, EGFR mutation, or ALK fusion) must have been previously treated with relevant t…

    Advanced Solid Tumor

  49. Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2022 NCT05308446

    CetuximabEncorafenib FDA EUNivolumab

    Participants must have BRAF\^V600E mutated colorectal cancer as tested in a Clinical Laboratory Improvement Act (CLIA)-certi…

    Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8

  50. Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

    Active, not recruiting Phase 2 UNICANCER Started 2022 NCT04074096

    Binimetinib Oral TabletEncorafenib Oral Capsule FDA EUPembrolizumab

    Presence of BRAFV600E/K/D/R mutation according to a locally validated BRAF Assay.

    Malignant Melanoma, BRAF V600 Mutation, Brain Metastases

  51. A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

    Active, not recruiting Phase 2 Pfizer Started 2022 NCT05217446

    Encorafenib FDA EUCetuximabPembrolizumab

    Locally confirmed BRAF V600E mutation in tumor tissue or blood

    Metastatic Colorectal Cancer

  52. FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

    Recruiting Phase 2 Sun Yat-sen University Started 2022 NCT05727163

    DexamethasoneAnisodamineOxaliplatinLeucovorinFluorouracilIrinotecan

    Patients with mutated RAS and BrafV600E

    Colorectal Cancer Metastatic

  53. Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

    Active, not recruiting Phase 2 Pierre Fabre Medicament Started 2022 NCT05195632

    Encorafenib FDA EUBinimetinib

    Presence of B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) V600E mutation in tumor tissue previously determined by a local assay at any time prior to scre…

    Non-Small Cell Lung Cancer

  54. ENCOrafenib With Binimetinib in bRAF NSCLC

    Active, not recruiting Phase 2 Intergroupe Francophone de Cancerologie Thoracique Started 2021 NCT04526782

    Encorafenib 75 MG FDA EUBinimetinib 15 MG

    Presence of a BRAFV600E mutation in lung cancer tissue as determined by a local laboratory assay.

    Non Small Cell Lung Cancer, BRAF V600E

  55. Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

    Active, not recruiting Phase 1/2 National Cancer Institute (NCI) Started 2021 NCT04557956

    Dabrafenib Mesylate FDA EUTazemetostat HydrobromideTrametinib Dimethyl Sulfoxide

    Patient must have a diagnosis of BRAF\^V600E/K-mutated metastatic melanoma

    Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma

  56. Combination Therapy for the Treatment of Diffuse Midline Gliomas

    Recruiting Phase 2 University of California, San Francisco Started 2021 NCT05009992

    ONC201PaxalisibDNX-2401

    BRAFV600E

    Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant

  57. Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2021 NCT04675710

    Dabrafenib FDA EUPembrolizumabTrametinib

    Must have a BRAFV600E mutation-positive tumor, as determined by BRAF V600E immunohistochemistry on tumor tissue…

    Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma

  58. A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

    Active, not recruiting Phase 1/2 Pediatric Brain Tumor Consortium Started 2020 NCT04201457

    Dabrafenib FDA EUTrametinibHydroxychloroquine

    Stratum 1 LGG or HGG with BRAF V600E/D/K mutation

    Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1

  59. PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

    Active, not recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2020 NCT04544111

    TrametinibDabrafenib FDA EUPDR001

    V600E, V600K, V600D).

    Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer

  60. Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

    Active, not recruiting Phase 2 SWOG Cancer Research Network Started 2020 NCT04268550

    Selpercatinib

    …izing mutations, EGFR T790M, ALK gene fusion, ROS1 gene fusion, KRAS activating mutation, BRAF V600E mutation and MET exon 14 skipping mutation or high-level amplification and expression

    Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

  61. Laser Ablation of Papillary Thyroid Microcarcinoma

    Active, not recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2020 NCT04623801

    (b) Bethesda III, IV, V, or VI cytology AND BRAF V600E mutation, or

    Papillary Thyroid Microcarcinoma, Thyroid, Thyroid Cancer

  62. Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

    Active, not recruiting Phase 2 Providence Health & Services Started 2020 NCT04061980

    BinimetinibEncorafenib FDA EUNivolumab

    …cally (or cytologically) confirmed diagnosis of metastatic, radioiodine (RAI) refractory, BRAFV600E/M mutant differentiated thyroid cancer (DTC)

    BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma

  63. Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

    Active, not recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2020 NCT04238624

    Dabrafenib FDA EUTrametinib

    Pathological (histologically or cytologically) proven diagnosis of BRAF-V600E mutant ATC (a diagnosis that is noted to be consistent with ATC is acceptable)

    Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related Tumors

  64. Study of NEO-201 in Solid Tumors Expansion Cohorts

    Active, not recruiting Phase 1/2 Precision Biologics Started 2019 NCT03476681

    NEO-201 in combination with pembrolizumab

    Patients with EGFR, ALK1, ROS1 or BRAF V600E genomic tumor aberrations must have had disease progression on FDA-approved agents for th…

    Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer

  65. Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

    Active, not recruiting Phase 1/2 M.D. Anderson Cancer Center Started 2019 NCT04017650

    CetuximabEncorafenib FDA EUNivolumab

    Confirmation of BRAFV600E tumor as detected by a CLIA-certified laboratory.

    BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma

  66. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

    Active, not recruiting Phase 1/2 Eisai Started 2019 NCT04008797

    E7386LenvatinibDoxorubicinPaclitaxel

    BRAF inhibitor (in combination with cetuximab ± binimetinib) for BRAF V600E mutated tumors

    Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

  67. Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

    Active, not recruiting Phase 2 Alliance for Clinical Trials in Oncology Started 2018 NCT03224767

    Vemurafenib FDA EUCobimetinib FDA EU

    …roven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC

    BRAF V600E Mutation Present, Papillary Craniopharyngioma

  68. Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

    Active, not recruiting Phase 2 European Organisation for Research and Treatment of Cancer - EORTC Started 2018 NCT03235245

    Nivolumab + IpilimumabEncorafenib + Binimetinib FDA EU

    Presence of BRAF V600E or V600K mutation in tumor tissue prior to enrolment as per local assessment

    Unresectable Stage III Melanoma, Stage IV Melanoma

  69. Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

    Active, not recruiting Phase 2 Melanoma Institute Australia Started 2017 NCT02858921

    Dabrafenib FDA EUTrametinibPembrolizumab

    A positive V600E immunohistochemistry stain at study entry should be formally quantified with a local mole…

    Melanoma

  70. Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2017 NCT03181100

    Atezolizumab FDABevacizumabCobimetinib FDA EUNab-paclitaxelPaclitaxelVemurafenib FDA EU

    ADDITIONAL INCLUSION CRITERIA FOR BRAF MUTATION (COHORT 1): Patients with a BRAFV600E mutation being considered for the triplet combination (vemurafenib + cobimetinib + atezol…

    Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8

  71. Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2016 NCT04439292

    Dabrafenib Mesylate FDA EUTrametinib Dimethyl Sulfoxide

    Patients must have a BRAF V600E or, V600K, V600R or V600D mutation, or another aberration, as identified via the MATCH Ma…

    Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma

  72. Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2014 NCT02231775

    Dabrafenib FDA EUTrametinib

    BRAF mutation-positive melanoma (V600E or V600K) based on report from a Clinical Laboratory Improvement Amendments (CLIA) certif…

    Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7

  73. Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2014 NCT02196181

    Dabrafenib Mesylate FDA EUTrametinib Dimethyl Sulfoxide

    …ts must have histologically or cytologically confirmed stage IV or unresectable stage III BRAF V600E or BRAF V600K mutant melanoma

    Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma

  74. Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

    Active, not recruiting Phase 1/2 National Cancer Institute (NCI) Started 2014 NCT01989585

    Dabrafenib FDA EUNavitoclaxTrametinib

    Patients must have histologically confirmed, BRAF-mutant (V600E/K) melanoma (molecularly confirmed using validated, commercially available assay performe…

    Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma

  75. A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

    Recruiting Phase 1/2 University of Louisville Started 2012 NCT01638676

    Vemurafenib FDA EUMetformin

    Patients with histological confirmed BRAFV600E melanoma (Stage IIIC or Stage IV, American Joint Commission on Cancer);

    Status may be outdated, last updated 2021-10-29Melanoma

  76. Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2012 NCT01709292

    Vemurafenib (All Groups) FDA EUVemurafenib (Post Surgery) - Group A + C FDA EU

    BRAF V600E mutation detected in the primary tumor or the recurrent/persistent tumor.

    Thyroid Cancer

  77. Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

    Active, not recruiting Phase 1/2 National Cancer Institute (NCI) Started 2010 NCT01089101

    Selumetinib

    these patients must have both the BRAFV600E mutation and BRAF KIAA1549 fusion assessments done and if only one test was previously co…

    Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma

  78. Q702 for the Treatment of Patients With Hematologic Malignancies

    Recruiting Phase 1 Mayo Clinic Started 2025 NCT06712810

    Axl/Mer/CSF1R Inhibitor Q702

    …ith Erdheim-Chester disease or Langerhans histiocytosis who have received vemurafenib for BRAF V600E mutated disease or cobimetinib for disease with activating MAP2K alterations.

    Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified

  79. XL092 and Cemiplimab in BRAF WT Thyroid Cancer

    Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center Started 2025 NCT06902376

    CemiplimabXL092

    Must have BRAF V600E mutation-negative tumor, as determined by BRAF V600E immunohistochemistry on tumor tissue…

    Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors

  80. Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors

    Recruiting Phase 1 Guangzhou Xiling Biotechnology Started 2025 NCT07259889

    NK cell preparation

    …imens include fluorouracil or its derivatives, oxaliplatin, and irinotecan, Subjects with BRAF V600E mutation have used BRAF inhibitors, and subjects with MSI-H/dMMR need to have used PD-1/P…

    Advanced Solid Tumors (Phase 1)

  81. A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma

    Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine Started 2025 NCT07306299

    Glioma-related multi-target mRNA vaccines

    …IV glioma harboring one or more of the following mutations: H3.3K27M, H3.1K27M, H3.3G34R, BRAF V600E, PIK3CA H1047R, IDH1 R132H, or EGFRvIII.

    Glioma, High Grade

  82. Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

    Recruiting Phase 1 M.D. Anderson Cancer Center Started 2024 NCT05985954

    CetuximabUlixertinibEncorafenib FDA EU

    BRAF expansion Cohort: BRAF V600E mutation must be present

    Metastatic Colorectal Cancer

  83. Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

    Recruiting Phase 1 National Cancer Institute (NCI) Started 2024 NCT06102902

    BET Bromodomain Inhibitor ZEN-3694CetuximabEncorafenib FDA EU

    …confirmed and radiographically measurable metastatic colorectal adenocarcinoma with known BRAF V600E mutation, confirmed in a Clinical Laboratory Improvement Amendments (CLIA) certified labo…

    Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8

  84. A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

    Active, not recruiting Phase 1 HiFiBiO Therapeutics Started 2023 NCT05789069

    HFB200603Tislelizumab

    BRAF V600E positive: must have received at least 2 lines of therapy

    Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer

  85. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

    Recruiting Phase 1 Memgen Started 2022 NCT05076760

    MEM-288 Intratumoral InjectionNivolumabDocetaxel

    …received a BRAF inhibitor as monotherapy or in combination with other targeted agents for BRAF V600E mutant melanoma.

    Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer

  86. A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

    Active, not recruiting Phase 1 Pfizer Started 2022 NCT05355701

    PF-07799933binimetinibcetuximabmidazolamfluorouracilleucovorin

    Part 3 (Cohort 4) (BRAF V600E CRC): Minimum of 2 cycles of prior 5-FU based chemotherapy required.

    Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma

  87. A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

    Active, not recruiting Phase 1 HiFiBiO Therapeutics Started 2022 NCT05238883

    HFB200301Tislelizumab

    BRAF V600E mutant: must have received at least 2 lines of therapy

    Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma

  88. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Recruiting Phase 1 AbbVie Started 2021 NCT05005403

    AzirkitugBudigalimabBevacizumabTelisotuzumab Adizutecan

    …essed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, BRAFV600E or HER2, other targetable mutations targeted with locally approved therapy, TAS-102, Rego…

    Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer

  89. DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

    Active, not recruiting Phase 1 Daiichi Sankyo Started 2020 NCT04042701

    Trastuzumab deruxtecan (DS-8201a)Trastuzumab deruxtecan (DS-8201a)Pembrolizumab

    …known epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK), BRAF V600E mutation, or ROS1 fusion should have disease progression after treatment with at least on…

    Breast Cancer, Non-small Cell Lung Carcinoma

  90. A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

    Active, not recruiting Phase 1 Exelixis Started 2019 NCT03845166

    XL092Atezolizumab FDAAvelumab

    BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations

    Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer

  91. Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

    Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2013 NCT01947023

    Dabrafenib FDA EUDabrafenib Mesylate FDA EULapatinibLapatinib Ditosylate

    … must have measurable and histologically or cytologically confirmed thyroid cancer with a BRAF V600E or V600K (c. 1799 T to A and c.1799\_1800TG\>AA) mutation that is not considered curable …

    Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma

  92. [177Lu]Lu-AKIR001 First-in-human Study

    Recruiting Early Phase 1 Karolinska University Hospital Started 2026 NCT06639191

    [177Lu]Lu-AKIR001

    For BRAFv600E mutated tumours: BRAF/MEK inhibitors.

    Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma, Cancer Head and Neck, Cervix Carcinoma

  93. A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

    Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2025 NCT06610682

    PlixorafenibRetifanlimab

    Histologic diagnosis of a primary CNS tumor with documented BRAF-V600E mutation by a CLIA approved DNA or RNA-based sequencing test (NGS or RNAseq).

    BRAF V600E Mutation

  94. Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

    Active, not recruiting Early Phase 1 H. Lee Moffitt Cancer Center and Research Institute Started 2018 NCT03543969

    Encorafenib FDA EUBinimetinibNivolumab

    … must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600E mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical …

    Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma

  95. Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System

    Recruiting No phase Masaryk Memorial Cancer Institute Started 2026 NCT07870265

    V600E).

    Unresectable Metastatic Melanoma

  96. Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.

    Not yet recruiting No phase National Cancer Center, Korea Started 2025 NCT06971965

    Levothyroxin

    …mination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.

    Thyroid Cancer, Papillary Thyroid Carcinoma

  97. Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients

    Recruiting No phase Royal Marsden NHS Foundation Trust Started 2025 NCT07673861

    …able mutation (IDH1 mutation/HER2 amplification/FGFR2 fusion or rearrangement/NTRK fusion/BRAF V600E mutation/MMR deficiency \[dMMR\]), AND

    Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer

  98. Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer

    Not yet recruiting No phase National Cancer Center, Korea Started 2025 NCT06730893

    …mination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.

    Thyroid Cancer, Papillary Thyroid Carcinoma

  99. A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

    Recruiting No phase UNICANCER Started 2023 NCT05639413

    Histologically confirmed BRAFV600E metastatic colorectal cancer (mCRC), chemotherapy-naive in the metastatic setting or havi…

    Metastatic Colorectal Cancer, BRAF V600E Mutation Positive

  100. iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

    Not yet recruiting Phase 3 Scancell Started 2026 NCT07815574

    iSCIB1+Nivolumab & Ipilimumab

    Participant has BRAF mutation positive disease with evidence of rapid PD.

    Broad match: BRAF mutation (unspecified)Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer

  101. Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

    Recruiting Phase 3 OSE Immunotherapeutics Started 2024 NCT06472245

    OSE2101Docetaxel

    KRAS G12C and BRAF mutations) after Sponsor' agreement.

    Broad match: BRAF mutation (unspecified)Patients With Non-Small Cell Lung Cancer

  102. VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

    Recruiting Phase 3 Replimune Started 2024 NCT06264180

    Vusolimogene OderparepvecNivolumabNivolumab + RelatlimabPembrolizumabSingle-agent chemotherapy

    …apy must be the immediate prior line of treatment before randomization (for patients with BRAF mutation, see I 4).

    Broad match: BRAF mutation (unspecified)Advanced Melanoma

  103. Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

    Recruiting Phase 3 CarThera Started 2024 NCT05902169

    CarboplatinLomustineTemozolomide

    Known BRAF/ NTKR mutated patients

    Broad match: BRAF mutation (unspecified)Glioblastoma, Recurrent Glioblastoma, GBM

  104. DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

    Recruiting Phase 2/3 Cancer Research UK Started 2023 NCT05768178

    Vemurafenib FDA EUCobimetinib FDA EU

    Confirmed diagnosis of a malignancy harbouring any actionable BRAF V600 mutation using an analytically validated next-generation sequencing method.

    Broad match: BRAF V600 mutation (unspecified)Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms

  105. ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer

    Active, not recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris Started 2018 NCT03570021

    …vor of "papillary thyroid carcinoma" (Type 6 according to the Bethesda classification (or BRAF mutation found on cytology analysis) (Appendix 2)

    Broad match: BRAF mutation (unspecified)Thyroid Cancer

  106. Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

    Active, not recruiting Phase 3 National Cancer Institute (NCI) Started 2015 NCT02224781

    Dabrafenib Mesylate FDA EUIpilimumabNivolumabTrametinib Dimethyl Sulfoxide

    Patients must have BRAF V600 mutation, identified by a Food and Drug Administration (FDA)-approved test at a Clinical …

    Broad match: BRAF V600 mutation (unspecified)Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma

  107. Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

    Not yet recruiting Phase 2 Rapa Therapeutics Starts 2027 NCT06708455

    RAPA-201 Rapamycin Resistant T CellsChemotherapy Prior to RAPA-201 Therapy

    For patients with BRAF V600 mutation-positive tumors, prior therapy with a BRAF inhibitor alone or in combination wit…

    Broad match: BRAF V600 mutation (unspecified)Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV

  108. Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

    Not yet recruiting Phase 2 Nationwide Children's Hospital Starts 2027 NCT07206849

    Tovorafenib FDA EU

    …m A: Patients with intracranial, localized, non-pontine, and non-thalamic HGG harboring a BRAFV600 mutation (who do not meet criteria for Strata B or C).

    Broad match: BRAF V600 mutation (unspecified)High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV), Diffuse Intrinsic Pontine Glioma, High Grade Glioma

  109. Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    Recruiting Phase 1/2 Aminex Therapeutics Started 2026 NCT07287917

    AMXT 1501 DicaprateDFMOFulvestrantCapivasertibPembrolizumab

    iii.Patients with BRAF gene mutant melanoma must have had a prior treatment regimen (progressed or shown intolerance) that i…

    Broad match: BRAF mutation (unspecified)Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer

  110. Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

    Recruiting Phase 1/2 National Cancer Institute (NCI) Started 2026 NCT06965114

    CladribineRituximabTovorafenib FDA EU

    …ly confirmed diagnosis of classical hairy cell leukemia (HCL), including demonstration of BRAF V600E mutation by immunohistochemistry, molecular diagnostic testing, or polymerase chain react…

    Broad match: BRAF V600EHairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia

  111. Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

    Recruiting Phase 2 The Methodist Hospital Research Institute Started 2026 NCT07042685

    Fruquintinib Combined With Chemotherapy

    …arkers such as microsatellite instability-high (MSI-H) or B-Raf proto-oncogene mutations (BRAF mutations).

    Broad match: BRAF mutation (unspecified)Metastatic Colorectal Cancer (CRC)

  112. Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

    Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris Started 2026 NCT07483983

    ASP3082

    Patients who have known actionable genomic alterations (EGFR, BRAF, and MET mutations or ALK, ROS1, RET, NTRK fusions) must have exhausted the available targeted therapy and h…

    Broad match: BRAF mutation (unspecified)Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma

  113. Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors

    Recruiting Phase 2 Samsung Medical Center Started 2026 NCT07688356

    Belvarafenib

    Documented BRAF mutation, including point mutations (e.g., V600E) or BRAF fusion mutations.

    Broad match: BRAF V600EPrimary Brain Tumor, Metastatic Brain Tumor

  114. Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

    Not yet recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2026 NCT07365410

    FurmonertinibFurmonertinibcarboplatinpemetrexed

    Concurrent positive for other driver genes (ALK fusion, ROS1 fusion, RET rearrangement, BRAF mutation, NTRK fusion, MET mutation, KRAS mutation)

    Broad match: BRAF mutation (unspecified)Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation

  115. HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer

    Recruiting Phase 1/2 Haisco Pharmaceutical Group Started 2026 NCT07790510

    HSK42360-Na TabletsCetuximab (EGFR inhibitor)mFOLFOX6 Regimen (Oxaliplatin/Leucovorin/5-FU)FOLFIRI Regimen (Irinotecan/Leucovorin/5-FU)

    … (limited to PCR or NGS-based assays) must be provided prior to enrollment to demonstrate BRAF V600 mutation positivity;

    Broad match: BRAF V600 mutation (unspecified)Metastatic Colorectal Cancer (CRC)

  116. PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

    Recruiting Phase 2 Guangdong Association of Clinical Trials Started 2026 NCT07416058

    QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

    BRAF V600

    Broad match: BRAF V600 mutation (unspecified)Lung Adenocarcinoma

  117. A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance

    Not yet recruiting Phase 2 Jiangsu Cancer Institute & Hospital Started 2026 NCT07622550

    Serplulimab+Fruquintinib+XELOX

    Confirmed RAS/BRAF mutation by testing.

    Broad match: BRAF mutation (unspecified)Metastatic Colorectal Cancer (CRC)

  118. MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

    Recruiting Phase 1/2 Ann & Robert H Lurie Children's Hospital of Chicago Started 2025 NCT06712875

    Trametinib and NivolumabDabrafenib, trametinib, nivolumab FDA EU

    …atients with histologically confirmed diagnosis of pediatric low-grade glioma harboring a BRAFV600 mutation that is recurrent or progressive OR

    Broad match: BRAF V600 mutation (unspecified)Low Grade Glioma, High Grade Glioma

  119. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    Recruiting Phase 1/2 BioNTech Started 2025 NCT07070232

    BNT326PumitamigItraconazoleParoxetine

    …-L1 inhibitor, and, for participants with human gene that encodes a protein called B-Raf (BRAF) gene mutant melanoma, a prior treatment regimen that included vemurafenib, dabrafenib, or another BRA…

    Broad match: BRAF mutation (unspecified)Advanced Solid Tumor

  120. Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC

    Recruiting Phase 2 The First Affiliated Hospital of Xiamen University Started 2025 NCT06929936

    Trilaciclib combined with Docetaxel

    Definition of driver genes: EGFR (including 19del, L858R, S768I, L861Q, and/or G719X), BRAF V600E, NTRK, MET14 exon skipping mutation, RET, ROS1, etc.

    Broad match: BRAF V600ENon-Small Cell Lung Cancer, Myelosuppression

  121. PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

    Active, not recruiting Phase 2 Grupo Español Multidisciplinar de Melanoma Started 2025 NCT06906822

    enfortumab vedotinpembrolizumab

    BRAF mutated patients should have received BRAF/MEK inhibitors and PD1/PDL1 therapy c.

    Broad match: BRAF mutation (unspecified)Melanoma

  122. Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

    Recruiting Phase 2 Grupo Español Multidisciplinar de Melanoma Started 2025 NCT06887088

    Encorafenib + Binimetinib FDA EUcemiplimab+fianlimab

    A documented mutation in BRAF-V600 in the tumor tissue.

    Broad match: BRAF V600 mutation (unspecified)Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases

  123. A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy

    Not yet recruiting Phase 2 RenJi Hospital Started 2025 NCT06730932

    JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)

    Collect tumor tissue for PD-L1, CD8 expression level determination, and MSI, TMB, KRAS, BRAF, PIK3CA, NRAS, PTEN, EGFR, HER2, HRAS, KIT, MET, ROS1, POLE, POLD1, TP53 gene mutation detection

    Broad match: BRAF mutation (unspecified)Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy

  124. XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

    Not yet recruiting Phase 1/2 Xynomic Pharmaceuticals Started 2025 NCT05275374

    XP-102Trametinib

    Advanced malignant solid tumor patients with a BRAF V600 mutation (limited to melanoma, colorectal cancer, non-small cell lung cancer, or thyroid …

    Broad match: BRAF V600 mutation (unspecified)Cancer, BRAF V600 Mutation, Melanoma, Colorectal Cancer

  125. Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

    Recruiting Phase 2 University of California, San Francisco Started 2025 NCT07110246

    Dabrafenib FDA EUTrametinib

    …must have histologically confirmed LGG World Health Organization (WHO) Grade I or II with BRAF V600 mutation confirmed by immunohistochemistry or sequencing

    Broad match: BRAF V600 mutation (unspecified)BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma

  126. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

    Recruiting Phase 1/2 National Cancer Institute (NCI) Started 2024 NCT05896839

    IpilimumabNivolumabPrednisoneSirolimus

    For patients with BRAF-mutant melanoma, prior therapies include BRAF/MEK inhibitors

    Broad match: BRAF mutation (unspecified)Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8

  127. A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

    Not yet recruiting Phase 2 CSPC Started 2024 NCT06525350

    Glumetinib tabletsHB1801 (docetaxel, albumin-bound）Docetaxel

    …ations must be negative (including EGFR mutations, ALK fusion, ROS1 rearrangement fusion, BRAF V600 mutation, NTRK fusion, MET 14 exon skipping mutation, RET rearrangement, HER2 Mutations, …

    Broad match: BRAF V600 mutation (unspecified)Status may be outdated, last updated 2024-07-29Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression

  128. Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

    Recruiting Phase 2 Sun Yat-sen University Started 2024 NCT06547203

    CetuximabToripalimabIrinotecan

    …ested as RAS/BRAF V600E wild-type and negative ultraselected for mutations including: RAS/BRAF V600E/PIK3CA/PTEN/EGFR (ECD), HER2 and MET amplification, and ALK/RET/NTRK1 gene fusions.

    Broad match: BRAF V600EStatus may be outdated, last updated 2024-08-09Colorectal Cancer Metastatic

  129. Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

    Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024 NCT06440954

    Intrathecal pemetrexed

    …FR mutant, ALK fusion, ROS1 fusion, and other oncogenic alterations including RET fusion, BRAF mutation, NTRK fusion, KRAS mutation was confirmed by an accredited local laboratory.

    Broad match: BRAF mutation (unspecified)Status may be outdated, last updated 2024-06-04Non-Small Cell Lung Cancer

  130. Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

    Recruiting Phase 1/2 M.D. Anderson Cancer Center Started 2024 NCT06683755

    NivolumabRelatlimabIpilimumab

    BRAF V600 results need not be available at the time of study start.

    Broad match: BRAF V600 mutation (unspecified)Melanoma

  131. Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

    Recruiting Phase 1/2 Georgiamune Started 2024 NCT06425926

    GIM-531Anti-PD-1 monoclonal antibody

    BRAF (V600) mutant melanoma or NSCLC: Participants must have received no more than 3 prior lines of therapy …

    Broad match: BRAF V600 mutation (unspecified)Melanoma Stage IV, Solid Tumor

  132. Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

    Recruiting Phase 2 Sun Yat-sen University Started 2024 NCT06563999

    SunvozertinibCrizotinibPralsetinibLarotrectinibSavolitinibPyrotinib

    …ing mutations of EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET 14 exon, HER2, BRAF V600E, KRAS G12C, and ALK fusion.

    Broad match: BRAF V600ELung Cancer Stage III, Mutation

  133. A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

    Recruiting Phase 2 Fudan University Started 2023 NCT05954429

    serplulimabFruquintinib

    For patients with BRAF mutations, BRAF inhibitor therapy is recommended when drugs are available

    Broad match: BRAF mutation (unspecified)Colorectal Cancer

  134. Potential of Moderate Whole Body Hyperthermia to Enhance Response

    Recruiting Phase 2 Charite University, Berlin, Germany Started 2023 NCT05821166

    Malignant melanoma, treatment-naive stage IV with multiple metastases and missing BRAF-V600 mutation.

    Broad match: BRAF V600 mutation (unspecified)Status may be outdated, last updated 2023-04-20Oncology

  135. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

    Recruiting Phase 1/2 Obsidian Therapeutics Started 2023 NCT06060613

    OBX-115

    Participants with targetable BRAF mutations are not required to have received prior BRAF inhibitors.

    Broad match: BRAF mutation (unspecified)Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer

  136. Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma

    Active, not recruiting Phase 2 CCTU- Cancer Theme Started 2023 NCT05097378

    Encorafenib + Binimetinib FDA EUStandard Adjuvant Treatment

    AJCC 8th edition stage III (B/C/D), or extracranial oligometastatic stage IV BRAFV600 mutant melanoma, based on histological/cytological and radiological assessments for which…

    Broad match: BRAF V600 mutation (unspecified)Melanoma, Cancer

  137. Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

    Recruiting Phase 2 Guangdong Provincial People's Hospital Started 2023 NCT05800340

    ToripalimabNab paclitaxelPemetrexedCarboplatin

    …h Stage IIB-IIIB NSCLC which harbored rare driver alteration including RET fusions, BRAF (V600E or non-V600E but confirmed driver mutations), ERBB2 exon20 insertion, MET amplification (…

    Broad match: BRAF V600EStatus may be outdated, last updated 2023-04-05Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

  138. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    Recruiting Phase 1/2 Institut de Recherches Internationales Servier Started 2023 NCT05786924

    S241656FOLFOX6/FOLFOX7FOLFIRICetuximabPanitumumabGemcitabine

    Part 2A: Advanced/metastatic NSCLC with KRAS non-G12C mutations and/or BRAF mutations

    Broad match: BRAF mutation (unspecified)Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation

  139. A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

    Recruiting Phase 1/2 Iovance Biotherapeutics Started 2022 NCT05361174

    IOV-4001

    …t dose of anti-PD-1/PD-L1 blocking antibody and received BRAF/MEK inhibitor in those with BRAF mutations.

    Broad match: BRAF mutation (unspecified)Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

  140. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

    Recruiting Phase 1/2 Aulos Bioscience Started 2022 NCT05267626

    AU-007AldesleukinAvelumabNivolumab

    BRAF mutation: patients who refused BRAF+MEK inhibitor

    Broad match: BRAF mutation (unspecified)Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer

  141. Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

    Active, not recruiting Phase 2 Li Zhang, MD Started 2022 NCT05003037

    Surufatinib, Toripalimab, Pemetrexed, Carboplatin/Cisplatin

    BRAF mutation, ERBB2 (HER2) amplification/mutation, MET amplification, MET exon 14 skipping mutation, a…

    Broad match: BRAF mutation (unspecified)Non Small Cell Lung Cancer

  142. A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

    Active, not recruiting Phase 2 Universitair Ziekenhuis Brussel Started 2022 NCT05370807

    Regorafenib 40 MG Oral TabletTriplet therapy

    Patients with BRAFV600mutant melanoma must have failed treatment with a BRAF-(+/-MEK) inhibitor.

    Broad match: BRAF V600 mutation (unspecified)Melanoma Stage III, Melanoma Stage IV

  143. Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

    Recruiting Phase 2 University Hospital, Strasbourg, France Started 2022 NCT05180825

    TrametinibVinblastine

    Determination of a negative BRAFv600 mutation by immunohistochemistry and/or molecular methods

    Broad match: BRAF V600 mutation (unspecified)Grade 1 Glioma, Mixed Glio-neuronal Tumors, Pleomorphic Xanthoastrocytoma

  144. A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

    Active, not recruiting Phase 1/2 Immuneering Started 2022 NCT05585320

    IMM-1-104 Monotherapy (Treatment Group A)IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)IMM-1-104 + modified FOLFIRINOX (Treatment Group C)IMM-1-104 + dabrafenib (Treatment Group D) FDA EUIMM-1-104 + pembrolizumab (Treatment Group E)

    …d third line participants with unresectable stage III or stage IV cutaneous melanoma with BRAF mutation.

    Broad match: BRAF mutation (unspecified)Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)

  145. Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

    Active, not recruiting Phase 2 University of Utah Started 2021 NCT04409639

    Cobimetinib FDA EU

    …lts on peripheral blood or bone marrow demonstrating NRAS, KRAS, PTPN11, FLT3, CBL, JAK2, BRAF or NF1 mutations at variant allele frequency ≥ 5%.

    Broad match: BRAF mutation (unspecified)Chronic Myelomonocytic Leukemia (CMML)

  146. The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

    Active, not recruiting Phase 2 Yale University Started 2021 NCT04699123

    NC318 800 mgNC318 400 mgPembrolizumab

    …nts with NSCLC known to harbor an ALK rearrangement, ROS1 rearrangement, EGFR mutation or BRAF mutation known to be sensitive to FDA approved tyrosine kinase inhibitors (TKI), are only eligible…

    Broad match: BRAF mutation (unspecified)Advanced Non-small Cell Lung Cancer

  147. A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

    Recruiting Phase 2 Day One Biopharmaceuticals Started 2021 NCT04775485

    Tovorafenib FDA EU

    …ow-Grade Glioma Extension: a relapsed or progressive LGG with documented known activating BRAF alteration.

    Broad match: BRAF mutation (unspecified)Low-grade Glioma, Advanced Solid Tumor

  148. Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

    Recruiting Phase 2 M.D. Anderson Cancer Center Started 2021 NCT05026983

    BinimetinibEncorafenib FDA EU

    Presence of BRAFV600 mutation in tumor tissue previously determined by a local assay (including immunohistoche…

    Broad match: BRAF V600 mutation (unspecified)Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8

  149. A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

    Recruiting Phase 2 SWOG Cancer Research Network Started 2021 NCT04511013

    BinimetinibEncorafenib FDA EUIpilimumabNivolumab

    Participants must have BRAF-V600 mutant melanoma documented by a Clinical Laboratory Improvement Act (CLIA)-certified labo…

    Broad match: BRAF V600 mutation (unspecified)Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain

  150. Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

    Active, not recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris Started 2021 NCT04940325

    DS-1062a

    Participants who have known EGFR, BRAF, and MET mutation or ALK, ROS1, RET, NTRK fusion: one line of an approved targeted agent and one platinum-d…

    Broad match: BRAF mutation (unspecified)Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer

  151. Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

    Active, not recruiting Phase 2 Vyriad Started 2020 NCT04291105

    VV1Cemiplimab

    Note: Patients with BRAF V600-positive tumors with no clinically significant tumor-related symptoms nor evidence of rap…

    Broad match: BRAF V600 mutation (unspecified)Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer

  152. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    Recruiting Phase 2 Roche Started 2020 NCT04302025

    AlectinibEntrectinibVemurafenib FDA EUCobimetinib FDA EUPralsetinibAtezolizumab FDA

    BRAF V600 mutation, RET fusion, PD-L1 expression in ≥ 1% tumor cells as determined by Food and Drug…

    Broad match: BRAF V600 mutation (unspecified)Non-small Cell Lung Cancer

  153. A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

    Active, not recruiting Phase 1/2 Sapience Therapeutics Started 2020 NCT04478279

    ST101Temozolomide

    Patients that have BRAF mutated disease should also have received one line of appropriate targeted therapy iii.

    Broad match: BRAF mutation (unspecified)Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer

  154. A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

    Recruiting Phase 2 Centre Leon Berard Started 2020 NCT04116541

    HDM201RibociclibCabozantinibAlectinibRegorafenibTrametinib

    …r amplification and/or rearrangement of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, PDGFR, FGFR1-2, FLT3 and/or CSFR1, and/or amplification of the ligands, an…

    Broad match: BRAF V600 mutation (unspecified)Malignant Solid Tumor

  155. PLATFORM Study of Precision Medicine for Rare Tumors

    Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2020 NCT04423185

    Almonertinib 110 MGDacomitinib 45 MGAlectinib 150 MGCrizotinib 250 MGPyrotinib 160/80 MGImatinib 400 MG

    …n obtaining EGFR mutation, ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation, BRAF mutation, BRCA1/2 mutation, C-KIT mutation, HER-2 mutation HER-2 over expression/amplification, CD…

    Broad match: BRAF mutation (unspecified)Rare Tumor

  156. Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2020 NCT04324112

    binimetinibEncorafenib FDA EU

    Participants must have BRAF V600 mutation as confirmed from fresh bone marrow aspirate, peripheral blood sample, or lymph …

    Broad match: BRAF V600 mutation (unspecified)Hairy Cell Leukemia

  157. Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2020 NCT03919071

    Dabrafenib Mesylate FDA EUTrametinib Dimethyl Sulfoxide

    Newly diagnosed high-grade glioma with BRAF\^V600-mutation

    Broad match: BRAF V600 mutation (unspecified)Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma

  158. Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

    Active, not recruiting Phase 2 Novartis Started 2020 NCT04417621

    LXH254LTT462TrametinibRibociclib

    Participants with BRAFV600 mutant disease:

    Broad match: BRAF V600 mutation (unspecified)Melanoma

  159. Genetic Testing in Guiding Treatment for Patients With Brain Metastases

    Active, not recruiting Phase 2 Alliance for Clinical Trials in Oncology Started 2019 NCT03994796

    AbemaciclibPI3K Inhibitor paxalisibEntrectinibAdagrasib

    For melanoma, patients must have progressed after prior immune checkpoint blockade or for BRAF positive melanoma, BRAF/MEK inhibitors.

    Broad match: BRAF mutation (unspecified)CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation

  160. The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

    Recruiting Phase 2 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Started 2019 NCT03841617

    Thyrogen

    …F inhibitors are recommended by 2021 NCCN guidelines as one of the management options for BRAF mutant tumors(13,14)

    Broad match: BRAF mutation (unspecified)Thyroid Cancer

  161. Melanoma Metastasized to the Brain and Steroids

    Recruiting Phase 2 Inge Marie Svane Started 2018 NCT03563729

    Pembrolizumab Injection [Keytruda]Ipilimumab Injection [Yervoy]Nivolumab Injection [Opdivo]Encorafenib FDA EUBinimetinibDabrafenib FDA EU

    For arm E specifically: Tumor cells must harbor BRAF mutation.

    Broad match: BRAF mutation (unspecified)Status may be outdated, last updated 2023-07-13Malignant Melanoma

  162. Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

    Active, not recruiting Phase 2 Children's Oncology Group Started 2018 NCT03581292

    TemozolomideVeliparib

    Negative results for BRAFV600 mutation by next-generation sequencing (NGS)

    Broad match: BRAF V600 mutation (unspecified)Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma

  163. Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

    Active, not recruiting Phase 1/2 Roswell Park Cancer Institute Started 2017 NCT02650986

    CyclophosphamideDecitabineTGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes

    …ed or is intolerant of a BRAF inhibitor or the combination of BRAF and MEK inhibitors for BRAFv600 mutant melanoma and a PD-1 inhibitor as monotherapy or in combination

    Broad match: BRAF V600 mutation (unspecified)Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma

  164. Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2017 NCT03175432

    Atezolizumab FDABevacizumabCobimetinib FDA EU

    Patients that are known to have BRAFV600 mutation must have received prior BRAFi/MEKi prior to enrolling on TACo.

    Broad match: BRAF V600 mutation (unspecified)BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain

  165. Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2016 NCT02910700

    BinimetinibDabrafenib FDA EUEncorafenib FDA EUNivolumabTrametinib

    … With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

    Broad match: BRAF mutation (unspecified)Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7

  166. Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2015 NCT04439279

    Trametinib Dimethyl Sulfoxide

    …: Phase II Study of Trametinib in Patients With BRAF Fusions, or With NonV600E, Non-V600K BRAF Mutations

    Broad match: BRAF mutation (unspecified)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma

  167. Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

    Active, not recruiting Phase 2 UNICANCER Started 2014 NCT02304809

    Vemurafenib FDA EU

    Patient with BRAF V600 mutation determined by the INCa platforms on the primary and/or metastatic lesion in the …

    Broad match: BRAF V600 mutation (unspecified)Solid Tumors, Hematologic Cancers, Metastatic Cancers

  168. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2013 NCT01708954

    Cabozantinib S-malateErlotinib Hydrochloride

    …ma viral oncogene homolog (KRAS) mutation, v-raf murine sarcoma viral oncogene homolog B (BRAF) mutation, human epidermal growth factor receptor 2 (HER2) mutation, ret proto-oncogene (RET) rearr…

    Broad match: BRAF mutation (unspecified)Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

  169. A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

    Active, not recruiting Phase 1 Ipsen Started 2026 NCT07441707

    Tovorafenib FDA EU

    …rogressive low-grade glioma with a documented known activating BRAF alteration, including BRAF V600 mutations and KIAA1549:BRAF fusions, as identified through molecular assays as routinely …

    Broad match: BRAF V600 mutation (unspecified)Low-grade Glioma

  170. JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

    Recruiting Phase 1 Jecho Biopharmaceuticals Started 2026 NCT07603479

    JL19001, subcutaneous injection, 1 μg/kgJL19001, subcutaneous injection, 5 μg/kgJL19001, subcutaneous injection,10 μg/kgJL19001, subcutaneous injection,15 μg/kgJL19001, subcutaneous injection,20 μg/kgJL19001, subcutaneous injection,25 μg/kg

    For patients with BRAF V600, NRAS, or KITmutations, prior treatment must include at least one targeted therapy agains…

    Broad match: BRAF V600 mutation (unspecified)Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer

  171. Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

    Recruiting Phase 1 Haisco Pharmaceutical Group Started 2026 NCT07561554

    HSK42360-Na

    Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360-Na.

    Broad match: BRAF V600 mutation (unspecified)Solid Tumors (Phase 1)

  172. Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

    Recruiting Phase 1 Anusha Kalbasi Started 2025 NCT04119024

    CyclophosphamideFludarabine PhosphateIL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells

    …kpoint inhibitor and a BRAF inhibitor in combination with MEK inhibitor for patients with BRAF V600-activating mutation and is not considered to have an alternate treatment option with cura…

    Broad match: BRAF V600 mutation (unspecified)Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8

  173. A Study of DEG6498 in Participants With Solid Tumors

    Recruiting Phase 1 Degron Therapeutics Co. Started 2025 NCT07244835

    DEG6498

    Part 2: Patients with BRAF mutation positive tumors and HCC

    Broad match: BRAF mutation (unspecified)Malignant Neoplasms

  174. A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

    Recruiting Phase 1 Hefei TG ImmunoPharma Started 2025 NCT07376707

    TGI-5

    For patients with BRAF V600 mutations, treatment with BRAF and MEK inhibitors prior to initiation on trial is require…

    Broad match: BRAF V600 mutation (unspecified)CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma, NSCLC (Non-small Cell Lung Cancer)

  175. Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

    Recruiting Phase 1 Haisco Pharmaceutical Group Started 2025 NCT07158710

    HSK42360

    Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360.

    Broad match: BRAF V600 mutation (unspecified)Malignant Brain Tumors

  176. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

    Recruiting Phase 1 Nested Therapeutics Started 2024 NCT06326411

    NST-628

    Select BRAF alterations

    Broad match: BRAF mutation (unspecified)Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation

  177. Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

    Recruiting Phase 1 Haisco Pharmaceutical Group Started 2024 NCT06536400

    HSK42360

    Positive BRAF V600 mutation result confirmed prior to the administration of HSK42360.

    Broad match: BRAF V600 mutation (unspecified)Status may be outdated, last updated 2024-08-05Solid Tumors

  178. A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors

    Recruiting Phase 1 JiaRay Group Started 2024 NCT06783569

    JR8603

    Prior system standard therapy for patients with MSS or MSI-L/pMMR, RAS and BRAF mutation: should include bevacizumab monotherapy or in combination with FOLFIRI, and monotherapy (…

    Broad match: BRAF mutation (unspecified)Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer, Colorectal Cancer

  179. A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

    Recruiting Phase 1 CSPC Started 2024 NCT07110883

    SYS6023

    …1, receptor tyrosine kinase (ROS1) fusion, B-Raf Proto-Oncogene, serine/threonine kinase (BRAF) V600 mutation, Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion, Neurotrophic Tyrosine Rece…

    Broad match: BRAF V600 mutation (unspecified)Advanced Solid Tumor

  180. To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

    Recruiting Phase 1 Jiangsu Alphamab Biopharmaceuticals Started 2024 NCT06592417

    JSKN016 injection

    EGFR, ALK, ROS1, NTRK, BRAF V600, MET exon 14, RET, KRAS G12C, or HER2;

    Broad match: BRAF V600 mutation (unspecified)Status may be outdated, last updated 2024-09-19Advanced Malignant Solid Tumor

  181. JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

    Recruiting Phase 1 Jazz Pharmaceuticals Started 2023 NCT06108050

    JZP898Pembrolizumab

    Melanoma with known BRAFv600 mutation: received BRAF/MEKi therapy before this study.

    Broad match: BRAF V600 mutation (unspecified)Advanced Solid Tumor, Metastatic Solid Tumor

  182. Clinical Trial of PM54 in Advanced Solid Tumors Patients.

    Recruiting Phase 1 PharmaMar Started 2023 NCT05841563

    PM54

    BRAF-mutated melanoma: at least one prior line of target therapy for advanced disease with BRAF inhibi…

    Broad match: BRAF mutation (unspecified)Advanced Solid Tumor

  183. Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

    Recruiting Phase 1 National Cancer Institute (NCI) Started 2022 NCT05111561

    BET Bromodomain Inhibitor ZEN-3694Binimetinib

    … genomic alteration(s) activating RAS signaling including activating KRAS, NRAS, HRAS, or BRAF mutations, inactivating NF1 mutations, or BRAF fusions

    Broad match: BRAF mutation (unspecified)Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma

  184. Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

    Recruiting Phase 1 Rina Plattner Started 2022 NCT04903119

    Nilotinib 100mgNilotinib 200mgNilotinib 300mgNilotinib 400mgDabrafenib FDA EUTrametinib

    3.1.2 Patients must have a BRAF V600 mutation.

    Broad match: BRAF V600 mutation (unspecified)Metastatic Melanoma, BRAF Gene Mutation

  185. A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

    Active, not recruiting Phase 1 Pfizer Started 2022 NCT05538130

    PF-07799544PF-07799933

    Evidence of a BRAF V600 mutation

    Broad match: BRAF V600 mutation (unspecified)Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer

  186. Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

    Active, not recruiting Phase 1 AffyImmune Therapeutics Started 2020 NCT04420754

    AIC100 CAR T Cells

    Anaplastic Thyroid Cancer BRAF mutant after failure of or inability to tolerate BRAF- specific therapy

    Broad match: BRAF mutation (unspecified)Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer

  187. Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

    Active, not recruiting Phase 1 University Health Network, Toronto Started 2019 NCT03991819

    BinimetinibPembrolizumab

    Provide archival tumor tissue sample for KRAS/BRAF/STK11 mutation analysis or newly obtained core or excisional biopsy of a tumor lesion not previously irr…

    Broad match: BRAF mutation (unspecified)Non-small Cell Carcinoma

  188. Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

    Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2019 NCT03816332

    IpilimumabNivolumabPrednisoneTacrolimus

    BRAF-mutant melanoma: prior therapies include BRAF/MEK inhibitors

    Broad match: BRAF mutation (unspecified)Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8

  189. XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

    Active, not recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute Started 2016 NCT02721459

    XL888Vemurafenib FDA EUCobimetinib FDA EU

    Must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical …

    Broad match: BRAF V600 mutation (unspecified)Melanoma, Skin Cancer

  190. Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

    Recruiting Early Phase 1 Daniel Morgenstern Started 2024 NCT06381570

    Tovorafenib FDA EUVinblastine

    a) Progressive/Recurrent LGG (non-NF1) with documented BRAF or CRAF alteration as identified through molecular assays as routinely performed at CLIA or other similar ce…

    Broad match: BRAF mutation (unspecified)Low-grade Glioma

  191. Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

    Recruiting Early Phase 1 H. Lee Moffitt Cancer Center and Research Institute Started 2021 NCT04741997

    Encorafenib Pill FDA EUBinimetinib PillNivolumab

    Melanoma must have a BRAFV600 mutation (using a CLIA-validated assay), either stage III (B/C/D) or Stage IV (AJCC 8th e…

    Broad match: BRAF V600 mutation (unspecified)Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation

  192. Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma

    Not yet recruiting No phase Sona Nanotech Started 2026 NCT06870994

    Either BRAF positive (BRAF+) or BRAF negative (BRAF-).

    Broad match: BRAF mutation (unspecified)Cutaneous Metastatic Melanoma

  193. A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma

    Not yet recruiting No phase Fudan University Started 2024 NCT06553781

    Temozolomide、Fruquintinib、Cadonilimab

    … previous first-line therapy (cutaneous melanoma patients are excluded) and patients with BRAF V600 mutations need to be admitted after targeted therapy.

    Broad match: BRAF V600 mutation (unspecified)Status may be outdated, last updated 2024-08-14Malignant Melanoma

  194. Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness

    Not yet recruiting No phase Fudan University Started 2023 NCT05881746

    KRAS/NRAS/BRAF mutation or right-sidedness;

    Broad match: BRAF mutation (unspecified)Status may be outdated, last updated 2023-05-31Colorectal Carcinoma, Liver Metastases

  195. Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer

    Recruiting No phase Charite University, Berlin, Germany Started 2023 NCT05991102

    Patients with BRAF mutant tumors: BRAF inhibitor, MSI-H patients: Checkpoint-inhibition

    Broad match: BRAF mutation (unspecified)Status may be outdated, last updated 2023-12-21Refractory Metastatic Colorectal Cancer

  196. Active Surveillance of Papillary Thyroid Microcarcinoma

    Recruiting No phase Cedars-Sinai Medical Center Started 2016 NCT02609685

    …a or high clinical suspicion, or pathologically confirmed Bethesda III or IV nodules with BRAF mutation.

    Broad match: BRAF mutation (unspecified)Papillary Thyroid Microcarcinoma